PDF(Pubmed)
Abstract：
A range of recombinant monoclonal antibodies (rMAbs) have found application in treating diverse diseases, spanning various cancers and immune system disorders. Chinese hamster ovary (CHO) cells have emerged as the predominant choice for producing these rMAbs due to their robustness, ease of transfection, and capacity for posttranslational modifications akin to those in human cells. Transient transfection and/or stable expression could be conducted to express rMAbs in CHO cells. To bolster the yield of rMAbs in CHO cells, a multitude of approaches have been developed, encompassing vector optimization, medium formulation, cultivation parameters, and cell engineering. This review succinctly outlines these methodologies when also addressing challenges encountered in the production process, such as issues with aggregation and fucosylation.
摘要：
一系列重组单克隆抗体（rMAb）已在治疗多种疾病中得到应用，跨越各种癌症和免疫系统疾病。中国仓鼠卵巢（CHO）细胞已成为生产这些rMAb的主要选择，因为它们的鲁棒性，易于转染，以及类似于人类细胞的翻译后修饰能力。可以进行瞬时转染和/或稳定表达以在CHO细胞中表达rMAb。为了增强CHO细胞中rMAb的产量，已经开发了多种方法，包含向量优化，中等配方,栽培参数，和细胞工程。这篇综述简洁地概述了这些方法，同时也解决了生产过程中遇到的挑战，如聚集和岩藻糖基化问题。
